Precision BioSciences (DTIL) Set to Release Earnings on Monday

Key Points

• Precision BioSciences is expected to report Q3 2026 results before the market opens on November 2. Analysts forecast a loss of $0.85 per share and revenue of $1.38 million; the earnings call is scheduled for November 6.
• The company’s previous quarter fell short of expectations, reporting a $1.26-per-share loss versus the $0.80 loss analysts expected. Analysts project full-year and next-year losses of $3.33 and $1.86 per share, respectively.
• DTIL shares opened at $6.64, well below the consensus analyst price target of $32.25. While four analysts rate the stock Buy and one rates it Sell, recent firms have issued mixed views, including downgrades to Sell.

Precision BioSciences (NASDAQ:DTIL - Get Free Report) is anticipated to issue its Q3 2026 results before the market opens on Monday, November 2nd. Analysts expect the company to announce earnings of ($0.85) per share and revenue of $1.38 million for the quarter. Interested persons may review the information on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 6, 2026 at 9:30 AM ET.

Precision BioSciences (NASDAQ:DTIL - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($1.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.46). Precision BioSciences had a negative net margin of 96.73% and a negative return on equity of 72.52%. On average, analysts expect Precision BioSciences to post ($3.33) EPS for the current fiscal year and ($1.86) EPS for the next fiscal year.

Precision BioSciences Stock Performance

DTIL stock opened at $6.64 on Monday. Precision BioSciences has a 1-year low of $3.53 and a 1-year high of $9.62. The firm has a market cap of $183.26 million, a P/E ratio of -2.37 and a beta of 1.27. The business's 50 day moving average is $7.00 and its 200-day moving average is $7.22. The company has a current ratio of 12.82, a quick ratio of 12.82 and a debt-to-equity ratio of 0.50.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Wall Street Zen downgraded Precision BioSciences from a "hold" rating to a "sell" rating in a research report on Saturday, August 8th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Precision BioSciences in a research report on Wednesday, August 5th. Finally, HC Wainwright reiterated a "buy" rating on shares of Precision BioSciences in a research note on Monday, August 3rd. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $32.25.

Precision BioSciences Company Profile

Precision BioSciences, Inc is a biotechnology company developing gene-editing medicines using its proprietary ARCUS platform. ARCUS is based on engineered DNA-cutting enzymes designed to make targeted changes to genetic material, with the potential to remove, insert or correct DNA sequences in human cells.

The company's research and development activities have focused primarily on in vivo gene editing, in which therapeutic editing components are delivered directly into the body. Its development programs have included potential treatments for conditions such as chronic hepatitis B infection, Duchenne muscular dystrophy and certain rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.